Think of CGRP as a “chemical messenger” in your brain that acts like a loud volume knob for pain. During a migraine, your trigeminal nerves release a lot of this CGRP, which causes the blood vessels in your head to swell and creates inflammation. This is what leads to that intense, throbbing headache.
Scientists have developed a new generation of medications specifically designed to “turn down the volume” by blocking this chemical.
The Two Main Types of CGRP antagonists for Migraine
- Monoclonal Antibodies (The Long-Term Preventers): These are like a specialised “shield” injected into the body. They either grab onto the CGRP chemical itself or block the “docking station” (receptor) where it lands. The aim of these treatments are To stop migraines before they even start.
- Some examples of these drugs are Galcanezumab (Emgality) injections and Eptinezumab (Vyepti) IV infusion.
- Gepants: These are smaller molecules usually taken as a pill. Some linke Rimegepant, are designed to stop a migraine right when you feel it coming on, while others like Atogepant, can be taken regularly to prevent Migraine.
Do They Really Work?
The short answer is yes!
Research shows CGRP antagonists are much better at reducing the number of “migraine days” per month than a placebo (a sugar pill). Generally, 60% of migraineurs respond very well to CGRP antagonists.
The preventive injections such as Emgality, are among the most effective tools to manage migraine attacks. Moreover, Emgality has shown effectiveness in treating Period related migraines.
Are They Safe?
One of the biggest wins for these therapies is that they are very well-tolerated. Unlike older migraine treatments that could make you feel groggy or sick, CGRP antagonists have very few side effects and most people find them easy to stick with.
In Summary:
CGRP antagonists are a huge breakthrough because they were built specifically to fight the biology of migraines, rather than being repurposed drugs for other conditions such as anti-epileptic and anti-depressant medications.
Some studies suggest galcanezumab (Emgality) and fremanezumab may have slightly greater reductions in monthly migraine days in patients who previously failed other preventive treatment.
CGRP mAbs and gepants are both effective and well-tolerated options for migraine prevention and acute treatment, with no high-certainty evidence favouring one agent over another for most outcomes. Selection should be individualised based on patient characteristics, prior treatment response, and tolerability.
